Q2 2025 Insight Molecular Diagnostics Inc Earnings Call Transcript

Aug 11, 2025 / 09:00 PM GMT

Release Date Price: $2.61 (+1.56%)

Transcript 10-Q8-K

Key Points

Positve

Insight Molecular Diagnostics Inc (IMDX) has completed assay and workflow design improvements, which have been transferred to manufacturing, with the first kits shipped to beta sites in June.
The company is on track to submit its FDA product, Ref Assured DX, by the end of the year, maintaining the timeline communicated earlier.
IMDX has received positive feedback from transplant centers, with multiple centers validating the new assay.
The company has shown a positive predictive value of close to 80% by combining two scores algorithmically, potentially reducing false positives.
IMDX is preparing for a meaningful product launch in 2026, with plans to expand into additional solid organ transplant indications, starting with heart transplants.

Negative

The company's Q2 pharma services revenue came in under $500,000, reflecting a challenging revenue environment.
Initial second-generation RUO kits do not carry revenue as customers need free samples for validation, delaying revenue generation.
Operating expenses remain high due to increased investment in FDA-compliant software development and consulting fees tied to regulatory submission.
The company expects a cash burn of about $6 million per quarter until the commercial launch next year, with potential increases in Q3.
There is uncertainty regarding the FDA approval timeline, with potential unknowns that could affect the current trial or timeline assumptions.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

IMDX.OQ - Insight Molecular Diagnostics Inc
Q2 2025 Insight Molecular Diagnostics Inc Earnings Call
Aug 11, 2025 / 09:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Thank you everyone for joining. We'll start here shortly.

We still have a couple of people joining in, so give it a second more.

All right, everyone. Welcome and thank you for joining us to discuss Insight molecular diagnostics 2nd quarter 2025 results.

If you have not seen today's shareholder letter, please visit Insight Molecular diagnostics investor relations page at investors. IDXINC.com.

Today's prepared remarks built upon the information already shared in this robust letter.

Joining us today are Insight Molecular diagnostics, President and CEO Josh Riggs, Chief Science Officer Ecky Schutz, and CFO Andrea James.

We also have our analysts with us

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.